7-N-(2-([2-(gamma-L-glutamylamino)-ethyl]-dithio)-ethyl)-mitomycin C (KW-2149) is more active than mitomycin C on chemonaive and drug-resistant urothelial carcinoma cells

Urological Research

Volumn 26, Issue 4, 1998, Pages 243-247

  Rohde, Detlef ^a   Raffenberg, Gudrun ^a   Kaviani, Shapur ^a   Wolff, Johannes ^a   Jakse, Gerhard ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Intravesical treatment; KW 2149; Mitomycins; Transitional cell carcinoma; Urine

Indexed keywords

7 N [2 [[2 (GAMMA GLUTAMYLAMINO)ETHYL]DITHIO]ETHYL]MITOMYCIN C; MITOMYCIN C;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CARCINOMA; CANCER CHEMOTHERAPY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; URINE PH; UROTHELIUM;

ANTI-BACTERIAL AGENTS; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, TRANSITIONAL CELL; DRUG INTERACTIONS; DRUG RESISTANCE, NEOPLASM; HUMANS; HYDROGEN-ION CONCENTRATION; MITOMYCIN; MITOMYCINS; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS;

EID: 0031667902     PISSN: 03005623     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002400050052     Document Type: Article

References (32)

1. Ashizawa T, Okamoto A, Okabe M, Kohayashi S, Arai H, Saito H, Kasai M, Gomi K (1995) Characteristics of the antitumour activity of M-16 and M-18, major metabolites of a new mitomycin C derivative KW-2149, in mice. Anticancer Drugs 6:763
2. Bando T, Kasahara K, Shibata K, Numata Y, Heki U. Shirasaki H, Twasa K, Fujimura M, Matsuda T (1996) Modulation of sensitivity to mitomycin C and a dithiol analogue by tempol in non-small-cell lung cancer cell lines under hypoxia. J Cancer Res Clin Oncol 122:21
3. Bracken RB, Swanson DA, Johnson DE, de Furia D, von Eschenbach AC, Crooke S (1989) Role of intravesical mitomycin C in management of superficial bladder tumours. Urology 16:11
4. Bubenik J, Baresova M, Viklicky V, Jakoubkova J, Sainerova H, Donner J (1973) Established cell line of urinary bladder carcinoma (T24) containing tumor-specific antigen. Int J Cancer 11:765
5. Dirix L, Catimel G, Verdonk R, de Bruijn E, Tranchand B, Afiet C, van Oosterrom A (1995) Phase I and pharmacokinetic study of KW-2149 given by 24 h continuous infusion. Invest New Drugs 13:133
6. Dirix LY, Cheuens EE, van der Heyden S, van Oosteron AT, de Bruijn EA (1994) Cytotoxic activity of 7-N-(2-((2-(-gamma-L-glutamylamino)-ethyl)dithio)ethyl)-mitomycin C and metabolites in cell lines with different resistance patterns. Anticancer Drugs 5:343
7. Dracopoli NC, Fogh J (1983) Polymorphic enzyme analysis of cultured human tumor cell lines. J Natl Cancer Inst 70:469
8. Eickelmann P, Schulz WA, Rohde D, Schmitz-Dräger B, Sies H (1994) Loss of heterozygosity at the NAD(P)H:quinone oxidoreductase locus associated with increased resistance against mitomycin C in a human bladder carcinoma cell line. Biol Chem Hoppe-Seyler 375:439
9. Elliott AY, Bronson DL, Stein N, Fraley EE (1976) In vitro cultivation of epithelial cells derived from tumors of the human urinary tract. Cancer Res 36-365
10. Elliott AY, Cleveland P, Cervenka J, Castro AE, Stein N, Hakkala TR, Fraley EE (1974) Characterization of cell line from human transitional cell cancer of the urinary tract. J Natl Cancer Inst 53:1341
11. Fujii N, Arai H, Saito H, Kasai M, Nakano H (1993) Induction of protein-DNA complexes in HeLA S3 cells by KW-2149, a new derivative of mitocycin C. Cancer Res 53:4466
12. Ishioka C, Kanamaru R, Konishi Y, Ishikawa A, Shibata H, Wakui A (1990) Comparative studies on the action of 7-N-[2-[[2-(gamma-L-glutamylamino)ethyl]dithio]ethyl]mitomycin C and of mitomycin C on cultured HL-60 cells and isolated phage and plasmid DNA. Cancer Chemother Pharmacol 26:117
13. Kobayashi E, Okabe M, Kono M, Arai H, Kasai M, Gomi K, Lee JH, Inaba M, Tsuruo T (1993) Comparison of uptake of mitomycin C and KW-2149 by murine P388 leukemia cells sensitive or resistant to mitomycin C. Cancer Chemother Pharmacol 32:20
14. Kono M, Saitoh Y, Kasai M, Sato A, Shirahata K, Morimoto M, Ashizawa T (1989) Synthesis and antitumor activity of a novel water soluble mitomycin analog: (7-N-[2-[[-(gamma-L-glutamylamino)ehtyl]dithio]ethyl]mitomycin D. Chem Pharm Bull (Tokyo) 37:1128
15. Lee JH, Naito M, Tsuruo T (1994) Nonenzymatic reductive activation of 7-N-((2-([2-(gamma-L-glutamylamino)ethyl]dithio)ethyl))mitomycin C by thiol molecules: a novel mitomycin C derivative effective on mitomycin C-resistant tumor cells. Cancer Res 54:2398
16. Marshall CJ, Franks LM, Carbonell AW (1977) Markers of neoplastic transformation in epithelial cell lines derived from human carcinomas. J Natl Cancer Inst 58:1743
17. Mishina T, Oda K, Murata S, Ooe H, Mori Y, Takahashi T (1975) Mitomycin C bladder instillation therapy for bladder tumors. J Urol 114:217
18. Monks A, Scudicro D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A, Gray-Goodrich M, Campbell H, Mayo J, Boyd M (1991) Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 83:757
19. Morimoto M, Ashizawa T, Ohno H, Azuma M, Kobayashi E, Okabe M, Gomi K, Kono M, Saitoh Y, Kanda Y (1991) Antitumor activity of 7-N-[[2-[[2-(gamma-L-glutamylamino)ethyl]dithio]ethyl] mitomycin C. Cancer Res 51:110
20. Nayak SK, OToole C, price ZH (1977) A cell line from an anaplastic transitional cell carcinoma of human urinary bladder. Br J Cancer 35 142
21. Nishiyama M, Kim R, Jinushi K, Takagami S, Kirihara Y, Toge T (1989) Antitumor effect of KW2149, a new mitomycin derivative, administered by different modalities. In Vivo 3:375
22. Ohe Y, Nakagawa K, Fujiwara Y, Sasaki Y, Minato K, Bungo M, Niimi S, Horichi N, Fukuda M, Saijo N (1989) In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines. Cancer Res 49:4098
23. O'Toole C, Price ZH, Ohnuki Y, Unsgaard B (1978) Ultrastructure, karyology and immunology of a cell line originated from a human transitional cell carcinoma. Br J Cancer 38:64
24. Rasheed S, Gardner MB, Rongey RW, Nelson-Rees WA, Arnstein P (1977) Human bladder carcinoma: characterization of two new tumor cell lines and search for tumor viruses. J Natl Cancer Inst 58:881
25. Rigby CC, Franks LN (1970) Human tissue culture cell line from a transitional cell tumour of the urinary bladder: growth, chromosome pattern and ultrastructure. Br J Cancer 24:746
26. Rohde D, Brehmer B, Kapp T, Jakse G (1998) Induction of drug-resistant bladder carcinoma cells in vitro: impact on polychemotherapy with cisplatin, methotrexate and vinblastine (CMV). Urol Res 26:249-257
27. Shibata K, Kasahara K, Bando T, Nakatsumi Y, Fujimura M, Tsuruo T, Matsuda T (1995) Establishment and characterization of non-small cell lung cancer cell lines. Jpn J Cancer Res 86:460
28. Skehan P, Storeng R, Scudiero DA, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:1107
29. Soloway MS, Murphy WM, DeFuria MD, Crooke S, Finebaum P (1981) The effect of mitomycin C on superficial bladder cancer. J Urol 125:646
30. Sorber M, de Bruijn EA, Kockx M, Bultick J, van Oosterom AT, Denis L (1995) Effects and systemic uptake of the new mitomycin c analogue KW-2149 in beagle dogs after intravesical administration. Urol Res 23:157
31. Tsuruo T, Sudo Y, Asami N. Inaba M, Morimoto M (1990) Antitumor activity of a derivative of mitomycin, 7-N-[2-[[2-gamma-L-glutamylamino)ethyl]dithio]ethyl] mitomycin C (KW-2149). against murine and human tumors and a mitomycin C-resistant tumor in vitro and in vivo. Cancer Chemother Pharmacol 27:89
32. Walker C, Povey S, Parrington JM, Riddle PN, Knuechel R, Masters JRW (1990) Development and characterization of cisplatin-resistant human testicular and bladder tumor cell lines. Eur J Cancer 26:742